Cargando…
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
Levodopa is the most effective treatment in Parkinson’s disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicat...
Autores principales: | Antonini, Angelo, Abbruzzese, Giovanni, Barone, Paolo, Bonuccelli, Ubaldo, Lopiano, Leonardo, Onofrj, Marco, Zappia, Mario, Quattrone, Aldo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515921/ https://www.ncbi.nlm.nih.gov/pubmed/18728767 |
Ejemplares similares
-
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini, Angelo, et al.
Publicado: (2011) -
Monotherapy for partial epilepsy: focus on levetiracetam
por: Gambardella, Antonio, et al.
Publicado: (2008) -
Safety and efficacy of tolcapone in Parkinson’s disease: systematic review
por: Artusi, Carlo Alberto, et al.
Publicado: (2021) -
Toward more focused multimodal and multidisciplinary approaches for pain management in Parkinson’s disease
por: Cuomo, Arturo, et al.
Publicado: (2019) -
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients
por: Barone, P, et al.
Publicado: (2015)